Innovus Pharmaceuticals Inc. (fka INNV)

[Honeycomb777]

So, in Q1 2019 - sales from Xyralid and especially Diabasens (IN CANADA) should help offset some slumping sales of the lesser products sold only in USA.

IMO, Revs should fall into that $5.5 - $5.7M range for 1st 3 months of 2019. Thinking Loss from Operations in that $1.27M range for the 1st 3 months.

* Hoping those call center reps worked some cross-sale magic but not holding my breath. Wonder if sales contests were ever envoked like I suggested. I wonder if he cares ? ;) C'mon Boyd...do somethin/anythin